PPACA Impact and Opportunities for the Life Sciences Industry Explored
Following the Supreme Court’s decision to upheld PPACA in August 2012, the year ahead opens new challenges and opportunities for the life sciences industry. Some of the factors that will directly impact the industry include taxes, rebates, and transparency requirements along with recent regulatory approvals. Life sciences companies must have a complete understanding of how to effectively thrive through the challenges and how to take advantage of the opportunities to minimize the potential pitfalls PPACA can bring to their bottom line.
In a two-hour LIVE webcast, a panel of thought leaders assembled by the Knowledge Group will discuss the significant issues in the mix including:
- Biologics Price Competition and Innovation Act (BPCIA)
- Medical Device Tax
- Sunshine Act
- Role of PCORI and IPAB
- Accountable Care Organization (ACO) Model
- Best Practices
- And a lot more!
Kevin R. Sweeney, Chair, Life Science Group,
Polsinelli Shughart PC
Dr. Steven K. Stranne, Shareholder,
Polsinelli Shughart PC
- Keeping up with developments in the area of health care reform can feel like drinking from a fire hose. This presentation provides a practical checklist and explanation of how to evaluate the issues that warrant attention for life sciences companies pursuing reimbursement and coverage strategies in the U.S. marketplace for drugs, biologics, devices and other technologies.
- Learn how the new reimbursement models emerging from the Center for Medicare and Medicaid Innovation are changing the financial incentives for health care providers and how to navigate the changing environment.
- Learn about how the evolving area of quality measurement is designed to change physician behavior and has implications for life sciences companies. Changes in the measurement of quality under Medicare are found in the health reform law (PPACA), the recent “fiscal cliff” legislation, and new legislative proposals.
- Learn how new provisions on the coverage of preventive screening services are relevant to the products used to perform preventive services, as well as diagnostics and therapies that may be clinically indicated on the basis of such screenings.
- Although the initiative to promote comparative effectiveness research in PPACA has been slow to develop, learn about why this topic deserves the attention of life sciences companies.
Terry Hisey, Vice Chairman and U.S. Life Sciences Leader,
** Speaker Talking Points to be added soon.. **
Jerry Cacciotti, Partner,
Oliver Wyman Health & Life Sciences
** Speaker Talking Points to be added soon.. **
Who Should Attend:
- Biotech/Pharma Industry Lawyers
- Life Sciences and Health Care Practice Consultants/Advisors
- General Counsel
- Senior Management
- Senior Executives
- Professionals coming from Biotech and Pharmaceutical Firms
- Consultants & Clients in the Biotech and Pharmaceutical Industries
Kevin Sweeney is Chair of Polsinelli Shughart’s multidisciplinary Life Sciences practice group and a senior member of its Corporate Finance group. He has more than 30 years experience in handling mergers and acquisitions, public and private securities offerings, venture capital financing, technology transfer, and other complex financial and strategic transactions for clients in a wide variety of industries, with a special emphasis in serving as a strategic advisor to the top management of life science companies of all types and stages of development. He is a strategic partner to many emerging and growth companies, assisting in the development and implementation of their business, financial and legal goals.
Mr. Sweeney uses his broad contacts in the national scientific, academic, business and financial communities to assist numerous emerging, growth, and established entities that advance human health, animal health, plant science, “green” and industrial technologies, and biosafety and homeland security sciences, as well as computer and software technologies.
Kevin Sweeney is Chair of Polsinelli Shughart’s multidisciplinary Life Sciences practice group and a senior member of its Corporate Finance …
Steven K. Stranne is a physician and lawyer with over 18 years of experience in Washington, D.C. designing, implementing and overseeing complex legislative and regulatory initiatives involving Congress, the Centers for Medicare & Medicaid Services (CMS), numerous other federal agencies within the U.S. Department of Health and Human Services (HHS) and the Medicare Administrative Contractors. He currently serves as policy counsel to several large non-profit health care associations, and he represents numerous health care providers and manufacturers of pharmaceuticals, biologics and medical devices.
Dr. Stranne helps clients to develop and implement strategies to secure appropriate reimbursement, coding and coverage policies for new and existing medical technologies and clinical services. He also works with the boards and leadership of manufacturers, health care providers and associations to assist with strategic planning in the context of the evolving regulatory and reimbursement landscape for health care services, drugs and devices. He provides unique experience in shaping public policy and works to develop novel strategies for clients to achieve their objectives by combining his ability to understand the health care sector and to interpret and help shape the relevant clinical literature, legislation and federal regulations.
Steven K. Stranne is a physician and lawyer with over 18 years of experience in Washington, D.C. designing, implementing and …
R.T. (Terry) Hisey is the Vice Chairman and U.S. Life Sciences Leader for Deloitte LLP. In this role, Terry leads the firm’s service efforts in the areas of audit, tax, strategy, performance improvement and technology consulting to assist clients in achieving sustainable competitive advantage through strategic change. His Life Sciences experience spans the entire value chain including drug discovery & development, commercial operations, production & distribution, and regulatory compliance. As Chairman of the Life Sciences Advisory Board for Deloitte Research and Steering Committee member for the Deloitte Center for Health Solutions, Terry guides thought leadership and advises clients on transformative opportunities in the industry including comparative effectiveness, informatics, social media and globalization. In addition to his client work, Terry is a noted industry authority, frequent speaker, a Strategy Advisor to Pharmaceutical Executive Magazine, and guest lecturer at several schools including the University of Pennsylvania, and the University of California at Berkeley. Terry is also a member of several industry associations and advisory boards.
R.T. (Terry) Hisey is the Vice Chairman and U.S. Life Sciences Leader for Deloitte LLP. In this role, Terry leads …
Jerry is a Partner in Oliver Wyman’s Health and Life Sciences Practice. He is a trusted advisor to senior executives across pharma and biotech, advising them on their most important decisions — to enter new markets, to undertake acquisitions or to realign business models. His recent work has focused on helping pharma prepare for the value-based healthcare, driven in part by the Affordable Care Act and other reform efforts, crafting strategies to profit and win in the transition from ‘fee for service’ medicine and ‘unit volume’ to the world where value – low cost, high quality – commands price.
Before joining Oliver Wyman, Jerry was a Vice President at IMS Health, leading its Product & Portfolio Strategy practice. Earlier, Jerry led the Life Sciences practice at Strategic Decisions Group. Jerry holds a B.A. in International Relations and an M.B.A. from Stanford University.
Jerry is a Partner in Oliver Wyman’s Health and Life Sciences Practice. He is a trusted advisor to senior executives …
Print and review course materials
Method of Presentation:
NASBA Field of Study:
NY Category of CLE Credit:
Unlock All The Knowledge and Credit You Need
Leading Provider of Online Continuing Education
It's As Easy as 1, 2, 3
Get Your 1-Year All Access Pass For Only $199
About Polsinelli Shughart PC
About Deloitte LLP
The multidisciplinary strengths of Deloitte’s Life Sciences practice offer the comprehensive resources necessary to address the wide range of transformative issues affecting early-stage, emerging and established life sciences companies. From inception and incorporation, to an initial public offering or a new global product launch, our people have the experience that life sciences companies require to address the unique needs of their expanding business around the world.
About Oliver Wyman Health & Life Sciences
Oliver Wyman is a global leader in management consulting. With offices in 50+ cities across 25 countries, Oliver Wyman combines deep industry knowledge with specialized expertise in strategy, operations, risk management, and organization transformation. The firm’s 3,000 professionals help clients optimize their business, improve their operations and risk profile, and accelerate their organizational performance to seize the most attractive opportunities. Oliver Wyman is a wholly owned subsidiary of Marsh & McLennan Companies [NYSE: MMC]. For more information, visitwww.oliverwyman.com. Follow Oliver Wyman on Twitter @OliverWyman.